Ova is a bioactive macrocyclic diterpenoid compound purified from the traditional Chinese herbal medicine Anisomeles indica (L.)Kuntze, with documented antiinflammatory, antiangiogenesis, antibacterial, antiviral, antioxidant, and anticancer activities [14, 15], however, nothing is known about the therapeutic effect of Ova in hematologic cancers, more so, regarding their ability to target and/or inhibit the CD34+/CD38− hCSCs, therefore, in this study, we investigated the microRNA (miRNA)-mediated epigenetically therapeutic effect of Ova in the CML hCSCs and its underlying molecular mechanism. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.